Reproductive and Developmental Biology

  • 제34권4호
  • /
  • Pages.289-297
  • /
  • 2010
  • /
  • 1738-2432(pISSN)
  • /
  • 2288-0151(eISSN)
한국동물번식학회 (The Korean Society of Animal Reproduction)
권호 표지

Biological Activity of Human Dimeric Hyperglycosylated Erythropoietin (dHGEPO) Fusion Proteins

  • Naidansuren, Purevjargal (Animal Biotechnology, Graduate School of Bio. & Information Technology, Institute of Genetic Engineering, Hankyong National University) ;
  • Min, Kwan-Sik (Animal Biotechnology, Graduate School of Bio. & Information Technology, Institute of Genetic Engineering, Hankyong National University)
  • 투고 : 2010.11.19
  • 심사 : 2010.12.03
  • 발행 : 2010.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Erythropoietin (EPO) is a glycoprotein hormone secreted from primarily cells of the peritubular capillary endothelium of the kidney, and is responsible for the regulation of red blood cell production. We constructed and expressed dimeric cDNAs in Chinease hamster ovary (CHO) cells encoding a fusion protein consisting of 2 complete human EPO domains linked by a 2-amino acid linker (Ile-Asp). We described the activity of dimeric hyperglycosylated EPO (dHGEPO) mutants containing additional oligosaccharide chains and characterized the function of glycosylation. No dimeric proteins with mutation at the $105^{th}$ amino acid were found in the cell medium. Growth and differentiation of the human EPO-dependent leukemiae cell line (F36E) were used to measure cytokine dependency and in vitro bioactivity of dHGEPO proteins. MIT assay at 24 h increased due to the survival of F36E cells. The dHGEPO protein migrated as a broad band with an average molecular mass of 75 kDa. The mutant, dHGEPO, was slightly higher than the wild-type (WT) dimeri-EPO band. Enzymatic N-deglycosylation resulted in the formation of a narrow band with a molecular mass twice of that of of monomeric EPO digested with an N-glycosylation enzyme. Hematocrit values were remarkably increased in all treatment groups. Pharmacokinetic analysis was also affected when 2.5 IU of dHGEPO were intravenously injected into the tails of the mice. The biological activity and half-life of dHGEPO mutants were enhanced as compared to the corresponding items associated the WT dimeric EPO. These results suggest that recombinant dHGEPO may be attractive biological and therapeutic targets.

키워드

참고문헌

  1. Benjamin LE, Franklin B (1999): Regulation of the erythropoietin gene. Blood 94:1864-1877.
  2. Broudy VC, Tait JF, Powell JS (1988): Recombinant human erythropoietin: Purification and analysis of carbohydrate linkage. Arch Biochem Biophys 265:329-336. https://doi.org/10.1016/0003-9861(88)90135-X
  3. Bunn HF (2007): New agents that stimulate erythropoiesis. Blood 109:868-872.
  4. Dalle B, Henri A, Rouyer-Fessard P, Bettan M, Scherman D, Beuzard Y, Payen E (2001): Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 15:3776-3782.
  5. Egrie JC, Brown JK (2001): Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16:3-13.
  6. Egrie JC, Brown JK (2002): Development and characterization of darbepoetin alfa. Oncology 16:13-22.
  7. Egrie JC, Dwer E, Browne JK, Hitz A, Lykos MA (2003): Darbepoitin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299. https://doi.org/10.1016/S0301-472X(03)00006-7
  8. Egrie JC, Strickand TW, Lane J, Aoki K, Cohen AM, Samlling R, Trail G, Lin FK, Browne JK, Hines DK (1986): Characterization and biological effects of recombinant human erythropoietin. Immunology 172: 213-244.
  9. Ellioitt S, Lorenzini T, Chang D, Barzilay J, Delorme E (1997): Mapping of the active site of recombinant human erythropoietin. Blood 89:493-502.
  10. Fares F, Ganem S, Hajouj T, Agai E (2007): Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin $\beta$-subunit to the coding sequence of human erythropoietin. Endocrinology 148:5081-5087. https://doi.org/10.1210/en.2007-0026
  11. Gross AW, Lodish HF (2006): Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J Biol Chem 281:2024-2032. https://doi.org/10.1074/jbc.M510493200
  12. JarGal N, Min KS (2009): Development and characterization of hyperglycosylated recombinant human erythropoietin (HGEPO). Reprod Dev Biol 33:77-83.
  13. Kim BS, JarGal P, Min KS (2007): Biological activity of recombinant human thrombopoietin. J of Life Science 17:1497-1504. https://doi.org/10.5352/JLS.2007.17.11.1497
  14. Lacombe C, Da Silva JL, Bruneval P (1988): Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81:620-623. https://doi.org/10.1172/JCI113363
  15. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasseer E (1986): Structural characterization of human erythropoietin. J Biol Chem 261:3116-3121.
  16. Lee HG, Lee PY, Kee YJ, Kim SJ, Chung HK, Seo MK, Park JK, Min KS, Chang WK (2003): Effects of changes in glycosylation sites on secretion of recombinant human erythropoietin in cultured CHO cells. Korean J Animal Reprod 27:299-307.
  17. Loo M, Beguin Y (1999): The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood 93:3286-3293.
  18. Macdougall IC (2002): Optimizing the use of erythropoietic agents-pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 17:66-70.
  19. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999): Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Mephol 10: 2392-2395.
  20. Min KS (2000): Biological functions of N- and O-linked oligisaccharides of equine chorionic gonadotropin and lutropin/choriogonadotropin receptor. Korean J Animal Reprod 24:357-364.
  21. Min KS (2001): Biosynthesis of a biological active single chain equine chorionic gonadotropin. J Life Science 11:103-107.
  22. Min KS, Hattori N, Aikawa K, Shiota K, Ogawa T (1996): Site-directed mutagenesis of recombinant equine chorionic gonadotropin/luteinizing hormone: differential role of oligosaccharides in luteinizing hormone and follicle-stimulating hormone-like activities. Endocrine J 43:585-593. https://doi.org/10.1507/endocrj.43.585
  23. Min KS, Hiyama T, Seong HH, Hattori S, Tanaka S, Shiota K (2004): Biological activities of tethered chorionic gonadotropin (eCG) and its deglycosylated mutants. J Reprod Dev 50:297-304. https://doi.org/10.1262/jrd.50.297
  24. Min KS, Shiota K, Saneyoshi T, Hirosawa M, Ogawa T (1997): Differential role of oligosaccharides in equine chorionic gonadotropin (eCG)/luteinizing hormone (LH) to express follicle stimulating hormone (FSH)- like and LH-like activities. J Reprod Dev 43: 177-179.
  25. Park JJ, JarGal N, Yoon JT, Min KS (2010): $\beta$-subunit 94-96 residues of tethered recombinant equine chorionic gonadotropin are important sites for luteinizing hormone and follicle stimulating hormone like activities. Reprod Dev Biol 34:33-40.
  26. Park JJ, Lee HG, Nam IS, Park HJ, Kim MS, Chung YH, JarGal N, Kang HY, Lee PY, Park JG, Seong HH, Chang WK, Min KS (2005): Biological activity of recombinant human erythropoietin (EPO) in vivo and in vitro. Reprod Dev Biol 29:69-79.
  27. Qiu H, Belanger A, Yoon HWP, Bunn HF (1998): Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem 273: 11173-11176. https://doi.org/10.1074/jbc.273.18.11173
  28. Sakaki H, Bothner B, Dell A, Fukuda M (1987): Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Bio Chem 27:24773-24778.
  29. Saneyoshi T, Min KS, Ma XJ, Nambo Y, Hiyama T, Tanaka S, Shiota K (2001): Equine follicle-stimulating hormone: Molecular cloning of $\beta$ subunit and biological role of the asparagines-linked oligosaccharide at $asparagine^{56}$ of $\alpha$ subunit. Biol Reprod 65:1686-1690. https://doi.org/10.1095/biolreprod65.6.1686
  30. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL (1999): An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773-24778. https://doi.org/10.1074/jbc.274.35.24773
  31. Takeuchi M, Inoue N, Strickand TW, Kobata M, Wada M, Shimizu R, Hoshi S, Kozutsumi H, Takasaki S, Kokbata A (1989): Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA 86:7819-7822. https://doi.org/10.1073/pnas.86.20.7819
  32. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL (1997a): Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 78:1505-1509.
  33. Wolf RF, Gilmore LS, Friese P, Downs T Burstein SA, Dale GL (1997b): Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 77:1020-1024.
  34. Wright NC, Farrell FX, Chang R (1996): Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458-463. https://doi.org/10.1126/science.273.5274.458